These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

116 related items for PubMed ID: 1343344

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Cytolytic activity of natural killer cells and lymphokine activated killer cells against hepatitis A virus infected fibroblasts.
    Baba M, Hasegawa H, Nakayabu M, Fukai K, Suzuki S.
    J Clin Lab Immunol; 1993; 40(2):47-60. PubMed ID: 7932628
    [Abstract] [Full Text] [Related]

  • 3. Assessment of human natural killer and lymphokine-activated killer cell cytotoxicity against Toxoplasma gondii trophozoites and brain cysts.
    Dannemann BR, Morris VA, Araujo FG, Remington JS.
    J Immunol; 1989 Oct 15; 143(8):2684-91. PubMed ID: 2477453
    [Abstract] [Full Text] [Related]

  • 4. IL-4 regulation of murine lymphokine-activated killer activity in vitro. Effects on the IL-2-induced expansion, cytotoxicity, and phenotype of lymphokine-activated killer effectors.
    Mulé JJ, Krosnick JA, Rosenberg SA.
    J Immunol; 1989 Jan 15; 142(2):726-33. PubMed ID: 2783444
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Lymphokine-activated killer cells in rats: analysis of tissue and strain distribution, ontogeny, and target specificity.
    Vujanovic NL, Herberman RB, Hiserodt JC.
    Cancer Res; 1988 Feb 15; 48(4):878-83. PubMed ID: 3257411
    [Abstract] [Full Text] [Related]

  • 8. Sensitivity of ovarian tumor cells to effector cells generated by various biological response modifiers.
    Nio Y, Zighelboim J, Berek JS, Bonavida B.
    Nat Immun Cell Growth Regul; 1990 Feb 15; 9(4):283-96. PubMed ID: 2215516
    [Abstract] [Full Text] [Related]

  • 9. Natural killer and lymphokine-activated killer cell activities from human marrow precursors. II. The effects of IL-3 and IL-4.
    Keever CA, Pekle K, Gazzola MV, Collins NH, Bourhis JH, Gillio A.
    J Immunol; 1989 Nov 15; 143(10):3241-9. PubMed ID: 2809200
    [Abstract] [Full Text] [Related]

  • 10. Cytokines alter target cell susceptibility to lysis: I. Evaluation of non-major histocompatibility complex-restricted effectors reveals differential effects on natural and lymphokine-activated killing.
    Wiebke EA, Custer MC, Rosenberg SA, Lotze MT.
    J Biol Response Mod; 1990 Apr 15; 9(2):113-26. PubMed ID: 2111373
    [Abstract] [Full Text] [Related]

  • 11. Lysis of human solid tumor cells by lymphokine-activated natural killer cells.
    Itoh K, Tilden AB, Balch CM.
    J Immunol; 1986 May 15; 136(10):3910-5. PubMed ID: 3084648
    [Abstract] [Full Text] [Related]

  • 12. LAK-cell-mediated cytotoxicity against tumor cell targets used to monitor the stimulatory effect of interleukin-2: cytotoxicity, target recognition and phenotype of effector cells lysing the Daudi, T24 and K562 tumor cell lines.
    Hermann GG, Zeuthen J, Claësson MH.
    Nat Immun; 1992 May 15; 11(1):7-16. PubMed ID: 1611282
    [Abstract] [Full Text] [Related]

  • 13. VLA-6 (CDw49f) is an important adhesion molecule in NK cell-mediated cytotoxicity following autologous or allogeneic bone marrow transplantation.
    Lowdell MW, Shamim F, Hamon M, Macdonald ID, Prentice HG.
    Exp Hematol; 1995 Dec 15; 23(14):1530-4. PubMed ID: 8542943
    [Abstract] [Full Text] [Related]

  • 14. Human oncogene-transfected tumor cells display differential susceptibility to lysis by lymphokine-activated killer cells (LAK) and natural killer cells.
    Lanza LA, Wilson DJ, Ikejiri B, Roth JA, Grimm EA.
    J Immunol; 1986 Oct 15; 137(8):2716-20. PubMed ID: 3489774
    [Abstract] [Full Text] [Related]

  • 15. The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: direct correlation between reduction of established metastases and cytolytic activity of lymphokine-activated killer cells.
    Mulé JJ, Yang J, Shu S, Rosenberg SA.
    J Immunol; 1986 May 15; 136(10):3899-909. PubMed ID: 2871106
    [Abstract] [Full Text] [Related]

  • 16. Natural killer and activated killer activities in chronic liver disease and hepatocellular carcinoma: evidence for a decreased lymphokine-induced activity of effector cells.
    Hirofuji H, Kakumu S, Fuji A, Ohtani Y, Murase K, Tahara H.
    Clin Exp Immunol; 1987 May 15; 68(2):348-56. PubMed ID: 2820634
    [Abstract] [Full Text] [Related]

  • 17. Analysis of the murine lymphokine-activated killer (LAK) cell phenomenon: dissection of effectors and progenitors into NK- and T-like cells.
    Kalland T, Belfrage H, Bhiladvala P, Hedlund G.
    J Immunol; 1987 Jun 01; 138(11):3640-5. PubMed ID: 3495566
    [Abstract] [Full Text] [Related]

  • 18. Synergistic action of a plant rhamnogalacturonan enhancing antitumor cytotoxicity of human natural killer and lymphokine-activated killer cells: chemical specificity of target cell recognition.
    Mueller EA, Anderer FA.
    Cancer Res; 1990 Jun 15; 50(12):3646-51. PubMed ID: 1692765
    [Abstract] [Full Text] [Related]

  • 19. Identification of a novel CD56- lymphokine-activated killer cell precursor in cancer patients receiving recombinant interleukin 2.
    McKenzie RS, Simms PE, Helfrich BA, Fisher RI, Ellis TM.
    Cancer Res; 1992 Nov 15; 52(22):6318-22. PubMed ID: 1384959
    [Abstract] [Full Text] [Related]

  • 20. Lymphokine-activated killer cells in rats. IV. Developmental relationships among large agranular lymphocytes, large granular lymphocytes, and lymphokine-activated killer cells.
    Maghazachi AA, Vujanovic NL, Herberman RB, Hiserodt JC.
    J Immunol; 1988 Apr 15; 140(8):2846-52. PubMed ID: 3258622
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.